▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Dec 26, 2013 by Todd Campbell

Celldex Therapeutics, Inc.: The Best-Performing Biotechs of 2013

Here's why Celldex Therapeutics, Inc. has posted a gain of over 200% this year.

Dec 26, 2013 by Todd Campbell

Anacor Pharmaceuticals Inc: The Best Performing Biotechs of 2013

Here's why Anacor Pharmaceuticals Inc. (Nasdaq: ANAC) has posted a gain of over 200% this year.

Dec 26, 2013 by Todd Campbell

Clovis Oncology: The Best-Performing Biotechs of 2013

Here's why Clovis Oncology Inc. (CLVS) has posted a gain of over 200% this year.

Dec 26, 2013 by Todd Campbell

Alnylam Pharmaceuticals, Inc.: The Best Performing Biotechs of 2013

Here's why Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has posted a gain of over 200% this year.

Dec 21, 2013 by Todd Campbell

Here's What You Need to Know about Rite-Aid's Frustrating Guidance

Rite-Aid surprised investors with a tepid outlook. But it may not be as bad as it seems.

Dec 18, 2013 by Todd Campbell

What Everyone Ought to Know About Johnson, Medivation, and Dendreon's Battle for Market Share in 2014

The battle to treat prostate cancer may get more heated in 2014 as Johnson (JNJ), Medivation (MDVN) and Dendreon (DNDN) vie for market share.

Dec 17, 2013 by Todd Campbell

What Everybody Ought to Know About athenahealth's Noisy 2014 Guidance

athenahealth's guidance for 2014 put investors on a roller coaster last week. Here's what you need to know about the forecast.

Dec 16, 2013 by Todd Campbell

Better Buy: Novo Nordisk Or Eli Lilly?

Novo Nordisk (NVO) and Eli Lilly (LLY) are giants when it comes to treating diabetes, but is one a better buy than the other?

Dec 13, 2013 by Todd Campbell

Celgene and Pharmacyclics Bring Big Change to Mantle Cell Lymphoma in 2013

Mantle cell lymphoma patients got new hope this year from newly approved drugs from Johnson (JNJ), Pharmacyclics (PCYC) and Celgene (CELG). But that hope comes at a steep price.

Dec 13, 2013 by Todd Campbell

Inovio's Game-Changing 2013

A big partnership with oncology giant Roche (RHHBY) sets the stage for Inovio (INO) in 2014.

Dec 12, 2013 by Todd Campbell

Better Buy: Merck or Bristol-Myers?

Merck (MRK) hopes to challenge Bristol-Myers (BMY) for melanoma market share. But does that make Merck a better bargain than Bristol?

Dec 11, 2013 by Todd Campbell

Here's How Obamacare Moves the Needle for Becton Dickinson

A rush of new patients and a wave of new treatments presents opportunity for Becton Dickinson (BDX)

Dec 11, 2013 by Todd Campbell

Gilead's Sofosbuvir Gets New Name, Price, Headaches

The highly regarded hepatitis C treatment is set to hit markets, but insurers may find its price too big a pill to swallow.

Dec 10, 2013 by Todd Campbell

Was 2013 the Beginning or the End for Opko Health?

Can this acquisitive, small-cap health-care company repeat 2013's stellar run in 2014?

Dec 7, 2013 by Todd Campbell

3 Lessons Big Pharma Learned From BioMarin in 2013

As investors look back at 2013, some of the most compelling lessons for succeeding in treating rare disease have been taught by BioMarin.

Dec 6, 2013 by Todd Campbell

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

Dec 6, 2013 by Todd Campbell

What's Behind Celgene's Spending Spree

Celgene (CELG) is making strikingly creative deals to keep pipelines filled with promising therapies, including Celgene's most recent partnership with stem cell player OncoMed (ONCO).

Dec 6, 2013 by Todd Campbell

What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs

With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK) rushing to get next generation hepatitis C drugs to market, here are the facts you need to see.

Dec 5, 2013 by Todd Campbell

Better Earnings: Celgene, Biogen, Or Amgen?

Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) all have blockbuster drugs kicking in billions of revenue. But, is one better than the other at turning that cash into profit?

Dec 5, 2013 by Todd Campbell

Soaring Hepatitis C Drug Prices Make Cures Costly

The arrival of Vertex's (VRTX) Incivek in 2010 kicked off a significant jump in the costs of treating hepatitis C. Those costs are likely to surge higher once Gilead's (GILD) and Johnson & Johnson's (JNJ) new drugs launch.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services